In the future, the identified biomarkers could be applied to facilitate the development of effective assays for prediction of mortality in HIV + TB+ patients, the discovery of new drugs and vaccines that could restoring the gene expression of these genes (PTPRCv1, CD3E, CCL5, and IL7R), and aid monitoring of treatment responses. The gene discussed is CCL5; the disease is tuberculosis.